Cite
HARVARD Citation
Richard, S. et al. (2021). A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert review of hematology. 14 (1), pp. 31-45. [Online].